Electronic Supplementary Material (ESI) for Chemical Science. This journal is © The Royal Society of Chemistry 2017

α-Perfluoroalkyl-β-alkynylation of Alkenes *via* Radical Alkynyl Migration

Xinjun Tang,† Armido Studer*†

Supporting information

Table of Contents

1.	Instrumentation and chemicals.	S1
2.	Preparation of propargylic alcohols 1	S2
3.	Reaction of propargylic alcohols 1 with perfluoroalkyl iodides 2	S10
4.	Follow-up chemistry	S23
5.	References	S25
6.	¹ H and ¹³ C NMR spectra of compounds 1, 3, 4 and 5.	S26

1. Instrumentation and chemicals

All reactions involving air- or moisture-sensitive reagents or intermediates were carried out in heat-gun-dried glassware under an argon atmosphere. For reactions with visible light a *Philips Master HPI-T Plus* (400 W) bulb was used. THF was freshly distilled from potassium under argon. All other solvents and reagents were purified according to standard procedures or were used as received from Aldrich, Acros Organics, Alfa Aesar. Propargylic alcohols **1** were synthesized according to literature procedures. H NMR and H NMR spectra were recorded on a Bruker DPX 300, a Bruker AV 300, a Bruker AV 400 at 300 K. The solvents residual proton resonance and the respective carbon resonance (CHCl₃, δ = 7.26 ppm for H NMR, δ = 77.0 ppm for H NMR) was used for calibration. Merck silica gel 60 F 254 plates were used for TLC, detection with UV light and dipping into a solution of KMnO₄ (1.5 g in 400 mL H₂O, 5 g of NaHCO₃), followed by heating. Flash column chromatography (FC) was performed using Merck or Fluka silica gel 60 (40-63 µm) with a pressure of 0.3 bar. IR spectra were recorded on a Digilab Varian 3100 FT-IR Excalibur Series. Melting points (M.P.) were determined on a *SMP 10 apparatus* (*Stuart Scientific*). Mass spectra were recorded on a Bruker MicroTof or an Orbitrap LTQ XL (Nanospray) of Thermo Scientific.

[†] Organisch-Chemisches Institut, Westfälische Wilhelms-Universität, Corrensstraße 40, 48149 Münster, Germany

^{*}E-mail: studer@uni-muenster.de

2. Preparation of propargylic alcohols 1

General procedure (GP1): Propargylic alcohols 1 were synthesized according to literature procedures.^[1] To a flame-dried flask equipped with a magnetic stir bar were added alkyne (5 mmol) and THF (35 mL). The mixture was then cooled to -78 °C. "BuLi (1.2 equiv) was added to it dropwise and the mixture maintained at this temperature for 15 min. Then the ketone (1 equiv) in 5 mL of THF was added dropwise at -78 °C. The reaction was allowed to warm to rt and stirring was continued overnight and then the reaction quenched with 50 mL of H₂O. The aqueous phase was extracted with 50 mL of ethyl acetate three times. The organic phase was combined and washed with 50 mL of brine, dried over Na₂SO₄, and concentrated. The residual was then purified by flash column chromatography (SiO₂) to obtain product 1.

3-Methyl-1-phenylhept-6-en-1-yn-3-ol (1a)

(100 MHz, CDCl₃) δ 138.37, 131.62, 128.29, 128.24, 114.92, 92.44, 83.69, 68.56, 42.67, 30.04, 29.36. **FTIR (neat)**: $\tilde{v} = 3376$, 2978, 2933, 1641, 1598, 1490, 1443, 1370, 1109 cm⁻¹.

3-Methyl-1-(p-tolyl)hept-6-en-1-yn-3-ol (1b)

OH 1b

1b was synthesized according to GP1: ¹**H NMR** (400 MHz, CDCl₃) $\delta 7.35 - 7.29$ (m, 2H), 7.15 - 7.07 (m, 2H), 5.99 - 5.83 (m, 1H), 5.16 - 4.96 (m, 2H), 2.47 - 2.32 (m, 5H), 2.09 (brs, 1H), 1.92 - 1.79 (m, 2H), 1.59 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 138.42, 138.36, 131.50, 128.98, 114.84, 91.75, 68.55, 42.71, 30.06, 29.36, 21.43. **FTIR** (**neat**): $\tilde{v} = 3363$, 2978, 2928, 1641, 1510,

1449, 1370, 1106 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for $C_{17}H_{14}OSNa$ ([M+Na]⁺): 237.1250, mass found: 237.1260.

1-(4-(Tert-butyl)phenyl)-3-methylhept-6-en-1-yn-3-ol (1c)

OH 1c

1c was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.12 (m, 4H), 5.88 – 5.62 (m, 1H), 5.10 – 4.77 (m, 2H), 2.35 – 2.11 (m, 3H), 1.85 – 1.61 (m, 2H), 1.46 (s, 3H), 1.17 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 151.44, 138.40, 131.32, 125.17, 119.66, 114.75, 91.90, 83.72, 68.47, 42.76, 34.66, 31.10, 30.02, 29.32. **FTIR** (neat): \tilde{v} = 3358, 2964, 1641, 1507, 1462, 1364, 1267, 1105 cm⁻¹. **HRMS** (ESI): Exact mass calculated for

C14H15ClONa ([M+Na]+): 279.1719, mass found: 279.1722.

3-Methyl-1-(p-tolyl)hept-6-en-1-yn-3-ol (1d)

OH 1d MeO

1d was synthesized according to GP1: ¹**H NMR** (300 MHz, CDCl₃) δ 7.46 – 7.34 (m, 2H), 6.92 – 6.79 (m, 2H), 6.06 – 5.82 (m, 1H), 5.23 – 4.98 (m, 2H), 3.83 (s, 3H), 2.52 – 2.31 (m, 2H), 2.19 (s, 1H), 1.96 – 1.78 (m, 2H), 1.61 (s, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 159.52, 138.43, 133.05, 114.83, 114.72, 113.84, 91.03, 83.54, 68.55, 55.25, 42.71, 30.09, 29.36. **FTIR** (**neat**): \tilde{v} =

3370, 2933, 1641, 1606, 1509, 1445, 1288, 1245, 1169, 1106, 1030 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for C₁₇H₁₄OSNa ([M+Na]⁺): 253.1199, mass found: 253.1201.

1-(4-Fluorophenyl)-3-methylhept-6-en-1-yn-3-ol (1e)

1e was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.51 – 7.37 (m, 2H), 7.13 – 6.94 (m, 2H), 6.06 – 5.77 (m, 1H), 5.24 – 4.97 (m, 2H), 2.50 – 2.30 (m, 2H), 2.21 (s, 1H), 1.95 – 1.83 (m, 2H), 1.61 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 164.14, 138.30, 133.56, 133.45, 115.65, 115.36, 114.90, 82.64, 68.51, 42.69, 29.99, 29.30. FTIR (neat): \tilde{v} = 3376, 3080, 2989, 2934,

1641, 1601, 1506, 1450, 1222, 1155, 1093 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for C₁₄H₁₅OFNa ([M+Na]⁺): 241.0999, mass found: 241.1009.

1-(4-Chlorophenyl)-3-methylhept-6-en-1-yn-3-ol (1f)

1f was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.39 – 7.35 (m, 2H), 7.33 – 7.28 (m, 2H), 6.00 – 5.86 (m, 1H), 5.19 – 4.99 (m, 2H), 2.48 – 2.30 (m, 2H), 2.15 (s, 1H), 1.95 – 1.82 (m, 2H), 1.61 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.24, 134.32, 132.85, 128.59, 121.14, 115.00, 93.42, 82.60, 68.55, 42.58, 29.96, 29.31. FTIR (neat): \tilde{v} = 3353, 2977, 2930, 1641,

1488, 1452, 1370, 1265, 1089, 1015 cm $^{-1}$. **HRMS (ESI)**: Exact mass calculated for $C_{14}H_{15}^{35}CIONa$ ([M+Na] $^+$): 257.0704, mass found: 257.0744.

3-Methyl-1-(m-tolyl)hept-6-en-1-yn-3-ol (1g)

1g was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.13 (m, 4H), 6.05 – 5.85 (m, 1H), 5.23 – 4.99 (m, 2H), 2.47 – 2.31 (m, 5H), 2.21 (s, 1H), 1.98 – 1.81 (m, 2H), 1.63 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.40, 137.91, 132.21, 129.14, 128.68, 128.13, 122.48, 114.84, 92.15, 83.85, 68.53, 42.74, 30.05, 29.34, 21.14. FTIR (neat): \tilde{v} = 3374, 2970, 2927, 2856,

1641, 1601, 1582, 1481, 1449, 1369, 1111 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for C₁₅H₁₈ONa ([M+Na]⁺): 237.1250, mass found: 237.1254.

3-Methyl-1-(o-tolyl)hept-6-en-1-yn-3-ol (1h)

1h was synthesized according to GP1: ¹**H NMR** (300 MHz, CDCl₃) δ 7.43 (d, J = 7.2 Hz, 1H), 7.30 – 7.12 (m, 3H), 6.05 – 5.86 (m, 1H), 5.22 – 4.99 (m, 2H), 2.54 – 2.36 (m, 5H), 2.29 (s, 1H), 2.00 – 1.83

(m, 2H), 1.66 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 140.04, 138.37, 131.90, 129.36, 128.28, 125.47, 122.42, 114.84, 96.59, 82.52, 68.69, 42.80, 30.17, 29.41, 20.65. **FTIR** (neat): $\tilde{v} = 3349$, 2977, 2926, 1641, 1485, 1452, 1370, 1117 cm⁻¹. **HRMS** (ESI): Exact mass calculated for C₁₅H₁₈ONa ([M+Na]⁺): 237.1250, mass found: 237.1258.

1-Mesityl-3-methylhept-6-en-1-yn-3-ol (1i)

OH 1i

1i was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 6.89 (s, 2H), 6.05 – 5.87 (m, 1H), 5.20 – 4.98 (m, 2H), 2.51 – 2.37 (m, 8H), 2.31 (s, 3H), 2.21 (s, 1H), 2.00 – 1.84 (m, 2H), 1.67 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 140.06, 138.47, 137.71, 127.54, 119.36, 114.80, 100.38, 81.37, 68.92, 42.92, 30.41, 29.53, 21.24, 20.93. **FTIR (neat)**: \tilde{v} = 3388, 2976, 2917, 2856,

1641, 1611, 1480, 1450, 1375, 1106, 1034 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for $C_{17}H_{22}ONa$ ($[M+Na]^+$): 265.1563, mass found: 265.1572.

1-(3,5-Dimethoxyphenyl)-3-methylhept-6-en-1-yn-3-ol (1j)

OH MeO 1j

1j was synthesized according to GP1: ¹**H NMR** (300 MHz, CDCl₃) δ 6.57 (d, J = 2.3 Hz, 2H), 6.43 (t, J = 2.3 Hz, 1H), 6.01 – 5.81 (m, 1H), 5.18 – 4.94 (m, 2H), 3.77 (s, 6H), 2.47 – 2.30 (m, 2H), 2.24 (brs, 1H), 1.90 – 1.79 (m, 2H), 1.59 (s, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 160.42, 138.32, 123.92, 114.92, 109.39, 101.69, 92.01, 83.63, 68.51, 55.39,

42.61, 29.98, 29.31. **FTIR** (**neat**): $\tilde{v} = 3381$, 2976, 2936, 2841, 1641, 1587, 1453, 1420, 1350, 1204, 1153, 1060 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for $C_{16}H_{20}O_3Na$ ([M+Na]⁺): 283.1305, mass found: 283.1317.

3-Methyl-1-(naphthalen-1-yl)hept-6-en-1-yn-3-ol (1k)

1k was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 8.34 – 8.26 (m, 1H), 7.90 – 7.79 (m, 2H), 7.67 (dd, J = 7.2, 1.2 Hz, 1H), 7.63 – 7.49 (m, 2H), 7.42 (dd, J = 8.3, 7.1 Hz, 1H), 6.05 – 5.88 (m, 1H), 5.21 – 4.99 (m, 2H), 2.58 – 2.40 (m, 2H), 2.28 (brs, 1H), 2.03 – 1.93 (m, 2H), 1.72 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.34 , 133.19 , 133.09 , 130.46 , 128.78 , 128.27 , 126.77 , 126.36 ,

125.94 , 125.12 , 120.22 , 115.01 , 97.46 , 81.73 , 68.86 , 42.78 , 30.22 , 29.50 . FTIR (neat): $\tilde{v} = 3352$, 3059, 2977, 2930, 2856, 1641, 1587, 1508, 1395, 1371, 1116 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{18}H_{18}ONa$ ([M+Na]⁺): 273.1250, mass found: 273.1256.

3-Methyl-1-(pyridin-2-yl)hept-6-en-1-yn-3-ol (11)

11 was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) $\delta\delta$ 8.60 (d, J = 4.5 Hz, 2H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.44 (dt, J = 7.8, 1.1 Hz, 1H), 7.25 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 6.03 – 5.81 (m, 1H), 5.21 – 4.92 (m, 2H), 2.76 (s, 1H), 2.53 – 2.28 (m, 1H), 1.98 – 1.85 (m, 2H), 1.65 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 149.87 , 142.92 , 138.24 , 136.15 , 127.09 , 122.88 , 114.88 , 92.78 , 82.95 , 68.29 , 42.43 , 29.79 , 29.17 . **FTIR** (neat): \tilde{v} = 3309, 2976, 2934, 1641, 1583, 1564, 1464, 1428, 1369, 1272, 1150 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₃H₁₅NONa ([M+Na]⁺): 224.1046, mass found: 224.1056.

1-Cyclohexyl-3-methylhept-6-en-1-yn-3-ol (1m)

1m was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 6.15 – 6.08 (m, 1H), 6.00 – 5.82 (m, 1H), 5.17 – 4.94 (m, 2H), 2.44 – 2.22 (m, 2H), 2.19 – 2.04 (m, 5H), 1.87 – 1.74 (m, 2H), 1.71 – 1.56 (m, 4H), 1.53 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.49 , 134.90 , 120.13 , 114.68 , 89.82 , 85.46 , 68.42 , 42.79 , 30.13 , 29.33 , 29.25 , 25.57 , 22.26 , 21.46 . FTIR (neat): \tilde{v} = 3397, 2929, 1641, 1437, 1369, 1136, 1110 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₄H₂₀ONa ([M+Na]⁺): 227.1406, mass found: 227.1414.

5-Methylundec-1-en-6-yn-5-ol (1n)

1n was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 6.02 – 5.76 (m, 1H), 5.19 – 4.91 (m, 2H), 2.42 – 2.16 (m, 4H), 2.06 (s, 1H), 1.85 – 1.65 (m, 2H), 1.60 – 1.35 (m, 7H), 0.93 (t, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.57 , 114.56 , 84.09 , 83.70 , 68.16 , 42.90 , 30.77 , 30.26 , 29.33 ,

21.87, 18.24, 13.53. FTIR (neat): $\tilde{v} = 3350$, 2959, 2932, 1642, 1455, 1369, 1125 cm⁻¹. HRMS (ESI):

Exact mass calculated for $C_{12}H_{20}ONa$ ([M+Na]⁺): 203.1406, mass found: 203.1413.

3-Methyl-1-(triisopropylsilyl)hept-6-en-1-yn-3-ol (10)

OH 10 was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 5.99 – 5.76 (m, 1H), 5.17 – 4.91 (m, 2H), 2.45 – 2.21 (m, 2H), 2.02 (s, 1H), 1.85 – 1.66 (m, 2H), 1.50 (s, 3H), 1.12 – 1.01 (m, 21H). ¹³C NMR (75 MHz, CDCl₃) 13C NMR (75 MHz, CDCl₃) δ 138.50, 114.79, 111.41, 83.80, 68.51, 42.77,

30.17, 29.47, 18.58, 11.15. **FTIR (neat)**: $\tilde{v} = 3381$, 2943, 2865, 1642, 1463, 1367, 1119, 1073 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for $C_{17}H_{32}OSiNa$ ([M+Na]⁺): 303.2115, mass found: 303.2124.

5-(Phenylethynyl)non-1-en-5-ol (1p)

1p was synthesized according to GP1: 1 H NMR (300 MHz, CDCl₃) δ 7.51 – 7.43 (m, 2H), 7.40 – 7.30 (m, 3H), 6.06 – 5.84 (m, 1H), 5.21 – 4.99 (m, 2H), 2.52 – 2.33 (m, 2H), 2.14 (s, 1H), 1.93 – 1.73 (m, 4H), 1.68 – 1.52 (m, 2H), 1.51 – 1.35 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H).. 13 C NMR (75 MHz, CDCl₃) δ 138.57, 131.65, 128.24, 122.82, 114.79, 91.82, 84.72, 71.60, 42.10, 41.14, 28.97, 26.51, 22.88, 14.05. FTIR (neat): $\tilde{v} = 3374$, 2956, 2934, 2862, 1641, 1599, 1490, 1443, 1379, 1340, 1256, 1135 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{17}H_{22}ONa$ ([M+Na]+): 265.1563, mass found:

3-Isopropyl-1-phenylhept-6-en-1-yn-3-ol (1q)

265.1566.

OH 1q was synthesized according to GP1: 1 H NMR (300 MHz, CDCl₃) δ 7.48 – 7.40 (m, 2H), 7.35 – 7.28 (m, 3H), 6.01 – 5.85 (m, 1H), 5.20 – 4.96 (m, 2H), 2.52 – 2.35 (m, 2H), 2.11 (s, 1H), 2.01 – 1.70 (m, 3H), 1.12 (d, J = 5.1 Hz, 3H), 1.09 (d, J = 5.1 Hz, 3H). 13 C NMR (75 MHz, CDCl₃) δ 138.77 , 131.64 , 128.22 , 128.19 , 122.86 , 114.73 , 90.86 , 85.38 , 74.96 , 38.37 , 37.88 , 28.87 , 17.97 , 17.09 . FTIR (neat): \tilde{v} = 3424, 2864, 1641, 1598, 1490, 1444, 1369, 1140, 1029 cm ${}^{-1}$. HRMS (ESI): Exact mass calculated for

1,3-Diphenylhept-6-en-1-yn-3-ol (1r)

 $C_{16}H_{20}ONa$ ([M+Na]⁺): 251.1406, mass found: 251.1410.

1r was synthesized according to GP1: yellow solid, **MP**: 69 °C; ¹**H NMR** (300 MHz, CDCl₃) δ 7.77 – 7.67 (m, 2H), 7.56 – 7.45 (m, 2H), 7.47 – 7.27 (m, 6H), 5.94 – 5.76 (m, 1H), 5.11 – 4.92 (m, 2H), 2.50 (s, 1H), 2.45 – 2.31 (m, 1H), 2.31 – 2.00 (m, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 144.62 , 138.09 , 131.74 , 128.54 ,

 $128.32 \ , 128.25 \ , 127.77 \ , 125.47 \ , 122.54 \ , 114.77 \ , 91.24 \ , 86.38 \ , 73.60 \ , 44.52 \ , 29.30 \ . \ \textbf{FTIR (neat)}:$ $\tilde{v} = 3273, \, 3070, \, 2945, \, 1641, \, 1489, \, 1449, \, 1388, \, 1306, \, 1014 \ \text{cm}^{\text{-}1}. \ \textbf{HRMS (ESI)}: \ \text{Exact mass calculated}$ for $C_{19}H_{18}ONa \ ([M+Na]^+): \, 285.1250, \, \text{mass found}: \, 285.1256.$

Chiral **1r** was synthesized according to GP1 and literature²: ¹**H NMR** (300 MHz, CDCl₃) δ 7.76 – 7.68 (m, 2H), 7.55 – 7.46 (m, 2H), 7.44 – 7.29 (m, 6H), 5.96 – 5.76 (m, 1H), 5.12 – 4.93 (m, 2H), 2.54 (s, 1H), 2.45 – 2.32 (m, 1H), 2.31 – 2.01 (m, 3H). The pure product was analyzed by chiral HPLC. Chiral HPLC (Chiralcel OD-H column with guard, 25 °C, 1 mL/min, cyclohexane:isopropanol = 90:10); Elution time: t_{major} = 14.6 min and t_{minor} = 23.0 min, enantiomeric excess (25%).

3,6-Dimethyl-1-phenylhept-6-en-1-yn-3-ol (1s)

OH Ph 1s **1s** was synthesized according to GP1: ¹**H NMR** (300 MHz, CDCl₃) δ 7.47 – 7.38 (m, 2H), 7.35 – 7.27 (m, 3H), 4.83 – 4.73 (m, 2H), 2.45 – 2.22 (m, 3H), 2.02 – 1.84 (m, 2H), 1.79 (s, 3H), 1.61 (s, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 145.72 , 131.61 , 128.21 , 122.71 , 110.17 , 92.53 , 83.65 , 68.63 , 41.61 , 33.13 , 29.97 ,

22.58 . FTIR (neat): $\tilde{v} = 3355$, 2978, 2931, 1649, 1599, 1490, 1444, 1374, 1341, 1261, 1201, 1118, 1099 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{15}H_{18}ONa$ ([M+Na]⁺): 237.1250, mass found: 237.1271.

3,7-Dimethyl-1-phenyloct-6-en-1-yn-3-ol (1t)

OH /

1t was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.48 – 7.39 (m, 2H), 7.35 – 7.27 (m, 3H), 5.27 – 5.16 (m, 1H), 2.46 – 2.14 (m, 3H), 1.84 – 1.76 (m, 2H), 1.73 – 1.70 (m, 3H), 1.68 (s, 3H), 1.59 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 132.44 , 131.62 , 128.21 , 128.17 , 123.87 , 122.84 , 92.78 ,

83.53 , 68.82 , 43.49 , 29.92 , 25.69 , 23.83 , 17.71 . **FTIR** (**neat**): $\tilde{v} = 3363$, 2971, 2919, 2854, 1598, 1490, 1444, 1375, 1267, 1186, 1117 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for $C_{16}H_{20}ONa$ ([M+Na]⁺): 251.1406, mass found: 251.1405.

4,4-Dimethyl-1,3-diphenylhept-6-en-1-yn-3-ol (1u)

OH
Ph
1u was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.74 – 7.66
(m, 2H), 7.55 – 7.47 (m, 2H), 7.40 – 7.30 (m, 6H), 5.98 – 5.81 (m, 1H), 5.13 –
5.00 (m, 2H), 2.50 (s, 1H), 2.40 – 2.27 (m, 2H), 1.05 (s, 6H). ¹³C NMR (75 MHz,
CDCl₃) δ 141.88 , 135.95 , 131.65 , 128.42 , 128.31 , 127.90 , 127.46 , 127.13 ,

122.77 , 117.38 , 92.18 , 86.36 , 79.72 , 42.63 , 41.92 , 28.25 , 22.48 , 21.60 . **FTIR (neat)**: $\tilde{v} = 3472$, 3065, 2971, 2938, 1727, 1683, 1599, 1491, 1444, 1385, 1364, 1312, 1255, 1171, 1162, 1046 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for $C_{21}H_{22}ONa$ ([M+Na]+): 313.1563, mass found: 313.1568.

3-Methyl-1-phenyloct-7-en-1-yn-3-ol (1v)

1v was synthesized according to GP1: ¹H NMR (300 MHz, CDCl₃) δ 7.50 – 7.40 (m, 2H), 7.39 – 7.30 (m, 3H), 5.97 – 5.77 (m, 1H), 5.15 – 4.96 (m, 2H), 2.24 – 2.11 (m, 2H), 2.06 (s, 1H), 1.87 – 1.67 (m, 4H), 1.61 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 138.51 , 131.64 , 128.23 , 122.77 , 114.76 , 92.83 , 83.40 , 68.55 , 43.19 , 33.70 , 29.94 , 24.07 . FTIR (neat): \tilde{v} = 3383, 3079, 2977, 2935, 2865, 2203, 1676, 1641, 1599, 1490, 1444, 1370, 1157 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₅H₁₈ONa ([M+Na]⁺): 237.1250, mass found: 237.1256.

3. Reaction of propargylic alcohols 1 with perfluoroalkyl iodides 2

General procedure 2 (GP2): To a flame-dried Schlenk tube equipped with a magnetic stir bar LiOH (0.42 equiv), LiHMDS (1.2 equiv), 1 (0.1 mmol), and 1.25 mL of DME were added sequentially under Ar atmosphere. The mixture was allowed to stir at room temperature for 0.5 h. After that DABCO (1.5 equiv), and 2 (1.8 equiv) were added to the reaction mixture under Ar atmosphere. Then the reaction mixture was stirred under visible-light irradiation (temperature up to 50 °C) for 18 h. After that, the solvent was removed and the residue was purified by flash column chromatography (SiO₂) to obtain product 3.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(phenylethynyl)decan-2-one (3a)

3a was synthesized according to GP2 with 1a (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L,

$$\begin{array}{c|c} O & & \\ \hline & & \\$$

0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3a** as a liquid (33 mg, 79%); 1 **H NMR** (300 MHz, CDCl₃) δ 7.39 (dd, J = 6.6, 3.2 Hz, 2H), 7.34 – 7.27 (m, 3H), 3.10 (ddd, J = 10.2, 5.0, 3.1 Hz, 1H), 2.83 – 2.65 (m, 2H), 2.58 – 2.22 (m, 2H), 2.19 (s, 3H), 2.11 – 1.96

(m, 1H), 1.89 - 1.74 (m, 1H). ¹³C **NMR** (75 MHz, CDCl₃) δ 207.44 , 131.59 , 128.28 , 128.18 , 89.26 , 40.89 , 36.21 (t, J = 20.9 Hz), 30.09 , 29.10 , 24.71 (t, J = 3.0 Hz). ¹⁹F **NMR** (282 MHz, CDCl₃) δ -81.02 (tt, J = 9.7, 3.4 Hz, 3F), -113.32 – -113.51 (m, 2F), -124.38 – -124.58 (m, 2F), -125.73 – -125.95 (m, 2F). **FTIR** (**neat**): $\tilde{v} = 2947$, 1718, 1599, 1491, 1443, 1356, 1217, 1131, 1110 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₈H₁₅OF₉Na ([M+Na]⁺): 441.0871, mass found: 441.0887.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(p-tolylethynyl)decan-2-one (3b)

O C₄F₉

3b was synthesized according to GP2 with **1b** (21 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3b** as a liquid (32 mg, 76%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.29 (d, J = 8.1 Hz, 2H), 7.14

-7.08 (m, 2H), 3.08 (ddd, J = 10.2, 5.0, 3.0 Hz, 1H), 2.84 - 2.63 (m, 2H), 2.34 (brs, 5H), 2.19 (s, 3H), 2.11 - 1.95 (m, 1H), 1.88 - 1.71 (m, 1H). ¹³C **NMR** (75 MHz, CDCl₃) δ 207.52 , 138.27 , 131.45 , 129.02 , 88.50 , 40.90 , 36.50 (d, J = 21.2 Hz), 36.22 , 35.95 , 30.07 , 29.13 , 24.76 (d, J = 3.0 Hz), 24.71 , 24.67 , 21.39 . ¹⁹F **NMR** (282 MHz, CDCl₃) δ -81.04 (tt, J = 9.7, 3.4 Hz, 3F), -113.34 - -113.55 (m, 2F), -124.37 - -124.64 (m, 2F), -125.73 - -125.99 (m, 2F). **FTIR** (**neat**): $\tilde{v} = 2946$, 1719, 1511, 1356, 1217,1131, 1021 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 455.1028, mass found: 455.1044.

5-((4-(*Tert*-butyl)phenyl)ethynyl)-7,7,8,8,9,9,10,10,10-nonafluorodecan-2-one (3c)

3c was synthesized according to GP2 with 1c (26 mg, 0.101 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column

chromatography (pentane/ethyl ether = 10/1) provided **3c** as a liquid (27 mg, 56%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.33 (s, 4H), 3.15 – 3.01 (m, 1H), 2.84 – 2.64 (m, 2H), 2.55 – 2.22 (m, 2H), 2.19 (s, 3H), 2.09 – 1.96 (m, 1H), 1.87 – 1.73 (m, 1H), 1.31 (s, 9H). ¹³**C NMR** (75 MHz, CDCl₃) δ 207.51 , 151.48 , 131.31 , 125.27 , 119.93 , 88.54 , 83.36 , 40.90 , 36.25 (t, J = 21.0 Hz), 34.73 , 31.15 , 30.08 , 29.14 , 24.71 (t, J = 3.0 Hz). ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.7, 3.4 Hz, 3F), -113.33 – -113.54 (m,

2F), -124.39 – -124.62 (m, 2F), -125.76 – -125.98 (m, 2F). **FTIR** (**neat**): $\tilde{v} = 2965$, 1719, 1355, 1217, 1163, 1131, 1107, 1017 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for $C_{22}H_{23}OF_9Na$ ([M+Na]⁺): 497.1497, mass found: 497.1504.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-((4-methoxyphenyl)ethynyl)decan-2-one (3d)

 $\begin{array}{c|c} O & & \\ \hline \\ C_4F_9 \\ \hline \\ 3d & \\ \hline \\ OMe \\ \end{array}$

3d was synthesized according to GP2 with **1f** (23 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3f** as a liquid (30 mg, 67%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.32 (d, J = 8.7 Hz, 2H), 6.83

(d, J = 8.7 Hz, 2H), 3.80 (s, 3H), 3.14 – 3.00 (m, 1H), 2.74 (dt, J = 8.4, 3.5 Hz, 2H), 2.55 – 2.21 (m, 2H), 2.19 (s, 3H), 2.01 (ddd, J = 8.6, 6.8, 3.9 Hz, 1H), 1.80 (ddd, J = 10.2, 5.9, 3.8 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.55 , 159.54 , 132.96 , 115.07 , 113.92 , 87.75 , 83.10 , 55.27 , 40.93 , 36.24 (t, J = 20.9 Hz), 30.08 , 29.16 , 24.72 (t, J = 2.9 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -81.04 (tt, J = 9.7, 3.3 Hz, 3F), -113.37 – -113.56 (m, 2F), -124.42 – -124.60 (m, 2F), -125.76 – -125.98 (m, 2F). FTIR (neat): $\tilde{v} = 2938$, 1718, 1608, 1511, 1444, 1365, 1290, 1232, 1219, 1172, 1132, 1107, 1031 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₉H₁₇O₂F₉Na ([M+Na]⁺): 471.0977, mass found: 471.0991.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-((4-fluorophenyl)ethynyl)decan-2-one (3e)

3e was synthesized according to GP2 with 1e (23 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column

chromatography (pentane/ethyl ether = 10/1) provided **3e** as a liquid (30 mg, 68%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.33 – 7.24 (m, 2H), 6.97 – 6.87 (m, 2H), 3.00 (ddt, J = 9.9, 8.2, 4.9 Hz, 1H), 2.77 – 2.55 (m, 2H), 2.50 – 2.15 (m, 2H), 2.12 (s, 3H), 2.02 – 1.88 (m, 1H), 1.81 – 1.65 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 207.36 , 162.43 (d, J = 249.2 Hz), 133.43 (d, J = 8.3 Hz), 118.99 (d, J = 3.5 Hz), 115.52 (d, J = 22.2 Hz), 88.92 (d, J = 1.5 Hz), 82.25 ,

40.84 , 36.14 (t, J = 21.0 Hz), 30.06 , 29.04 , 24.65 (t, J = 3.0 Hz). ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.04 (tt, J = 9.7, 3.3 Hz, 3F), -111.14 - -111.24 (m, 1F), -113.36 - -113.59 (m, 2F), -124.41 - -124.62 (m, 2F), -125.76 - -125.99 (m, 2F). **FTIR** (neat): $\tilde{v} = 2949$, 1718, 1603, 1508, 1356, 1218, 1157, 1132, 1015 cm⁻¹. **HRMS** (ESI): Exact mass calculated for C₁₈H₁₄OF₁₀Na ([M+Na]⁺): 459.0777, mass found: 459.0788.

5-((4-Chlorophenyl)ethynyl)-7,7,8,8,9,9,10,10,10-nonafluorodecan-2-one (3f)

O C₄F₉

3f was synthesized according to GP2 with **1c** (23 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3c** as a liquid (37 mg, 83%); ¹H NMR (300 MHz, CDCl₃) δ 7.26 – 7.18 (m, 4H), 3.01 (ddt,

J = 9.9, 8.2, 4.9 Hz, 1H), 2.75 – 2.54 (m, 2H), 2.48 – 2.15 (m, 2H), 2.12 (s, 3H), 1.94 (dq, J = 10.9, 3.9, 3.4 Hz, 1H), 1.80 – 1.68 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.30 , 134.22 , 132.80 , 128.60 , 121.40 , 90.28 , 82.23 , 40.81 , 36.08 (t, J = 21.0 Hz), 30.07 , 28.98 , 24.69 (t, J = 3.3 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.7, 3.3 Hz, 3F), -113.28 – -113.65 (m, 2F), -124.39 – -124.59 (m, 2F), -125.77 – -125.96 (m, 2F). FTIR (neat): $\tilde{v} = 2947, 1718, 1491, 1357, 1234, 1222, 1165, 1134, 10921016$ cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₈H₁₄O³⁵ClF₉Na ([M+Na]⁺): 475.0482, mass found: 475.0484.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(*m*-tolylethynyl)decan-2-one (3g)

3g was synthesized according to GP2 with 1g (21 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L,

$$\begin{array}{c|c} O & & \\ \hline & C_4 F_9 \\ \hline & 3g & \\ \hline \end{array}$$

0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided $3\mathbf{g}$ as a liquid (29 mg, 68%); $^1\mathbf{H}$ NMR (300 MHz, CDCl₃) δ 7.24 - 7.15 (m, 3H), 7.15 - 7.09 (m, 1H), 3.09 (ddt, J = 9.9, 8.0, 4.9 Hz, 1H), 2.83 - 2.64 (m, 2H), 2.55-2.23 (m, 5H), 2.19 (s, 3H), 2.07 - 1.96 (m, 1H), 1.80 (dd, J = 10.2, 6.0 Hz, 1H). $^{13}\mathbf{C}$ NMR (75 MHz, CDCl₃) δ 207.48 ,

137.97 , 132.13 , 129.05 , 128.64 , 128.16 , 122.72 , 88.83 , 83.43 , 40.87 , 36.19 (t, J = 21.0 Hz), 30.07 , 29.10 , 24.67 (t, J = 3.2 Hz), 21.14 . ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.02 (tt, J = 9.7, 3.3 Hz, 3F), -113.37 – -113.57 (m, 2F), -124.39 – -124.62 (m, 2F), -125.75 – -126.01 (m, 2F). **FTIR** (neat): $\tilde{v} = 2946$, 2361, 1719, 1487, 1356, 1234, 1134 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 455.1028, mass found: 455.1044.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(o-tolylethynyl)decan-2-one (3h)

O C₄F₉ **3h** was synthesized according to GP2 with **1h** (21 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3h** as a liquid

(33 mg, 78%); ¹H NMR (300 MHz, CDCl₃) δ 7.36 (dd, J = 7.3, 1.2 Hz, 1H), 7.23 – 7.16 (m, 2H), 7.16 – 7.08 (m, 1H), 3.14 (ddt, J = 9.8, 8.4, 4.8 Hz, 1H), 2.77 (td, J = 7.6, 6.9, 1.9 Hz, 2H), 2.54-2.23 (m, 5H), 2.19 (s, 3H), 2.11 – 1.98 (m, 1H), 1.87 – 1.76 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.44 , 140.02 , 131.94 , 129.42 , 128.18 , 125.51 , 122.70 , 93.19 , 82.20 , 40.88 , 36.37 (t, J = 21.1 Hz), 30.08 , 29.26 , 24.82 (t, J = 3.1 Hz), 20.57 . ¹⁹F NMR (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.7, 3.3 Hz, 3F), -113.12 – -113.51 (m, 2F), -124.43 – -124.65 (m, 2F), -125.75 – -126.00 (m, 2F). FTIR (neat): \tilde{v} = 2954, 1719, 1487, 1356, 1220, 1165, 1133, 1037 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 455.1028, mass found: 455.1045.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(mesitylethynyl)decan-2-one (3i)

3i was synthesized according to GP2 with 1i (24 mg, 0.099 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L,

C₄F₉ 3i

0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3i** as a liquid (28 mg, 61%); ¹H NMR (300 MHz, CDCl₃) δ 6.86 (s, 2H), 3.18 (dq, J = 13.2, 4.6 Hz, 1H), 2.88 – 2.70 (m, 2H), 2.55-2.23 (m, 11H), 2.18 (s, 3H), 2.12 – 1.98 (m, 1H), 1.88 – 1.74 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.45, 140.05, 137.57, 127.58, 119.64, 96.95, 80.97,

40.93, 36.60 (t, J = 21.1 Hz), 30.04, 29.49, 24.99 (t, J = 3.2 Hz), 21.22, 20.87. ¹⁹F NMR (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.7, 3.4 Hz, 3F), -112.86 - -113.59 (m, 2F), -124.44 - -124.68 (m, 2F), -125.78 -125.98 (m, 2F). FTIR (neat): $\tilde{v} = 2921, 2362, 2336, 1718, 1375, 1365, 1217, 1131, 1109, 1034,$ 1014 cm⁻¹. **HRMS (ESI)**: Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 483.1341, mass found: 483.1353.

5-((3,5-Dimethoxyphenyl)ethynyl)-7,7,8,8,9,9,10,10,10-nonafluorodecan-2-one (3j)

MeO ОМе 3j

3j was synthesized according to GP2 with 1j (26 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 µL, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 6/1) provided 3j as a liquid (27 mg, 57%); ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3) \delta 6.54 \text{ (d, } J = 2.4 \text{ Hz}, 2\text{H}), 6.43$ (t, J = 2.3 Hz, 1H), 3.78 (s, 6H), 3.08 (dt, J = 7.9, 5.0 Hz, 1H), 2.80 - 2.64 (m, 2H), 2.57 - 2.22 (m, 2H), 2.27 - 2.22 (m, 2H), 2.272H), 2.19 (s, 3H), 2.11 – 1.95 (m, 1H), 1.87 – 1.75 (m, 1H). 13 C NMR (75 MHz, CDCl₃) δ 207.47 ,


160.55, 124.22, 109.50, 101.53, 88.86, 83.26, 55.39, 40.87, 36.13 (t, J = 21.2 Hz), 30.11, 29.03, 24.67 (t, J = 2.9 Hz). ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.02 (tt, J = 9.7, 3.3 Hz, 3F), -113.29 – -113.57 (m, 2F), -124.34 - -124.66 (m, 2F), -125.75 - -125.96 (m, 2F). **FTIR** (neat): $\tilde{v} = 2945$, 1720, 1590, 1454, 1422, 1355, 1233, 1207, 1157, 1134, 1066 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{20}H_{19}O_3F_9Na$ ([M+Na]⁺): 501.1083, mass found: 501.1098.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(naphthalen-1-ylethynyl)decan-2-one (3k)

3k was synthesized according to GP2 with **1k** (25 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3k** as a liquid (33 mg, 71%); ¹**H NMR** (300 MHz, CDCl₃) δ 8.28 – 8.20 (m, 1H), 7.90 –

7.79 (m, 2H), 7.64 (dd, J = 7.2, 1.2 Hz, 1H), 7.61 – 7.48 (m, 2H), 7.42 (dd, J = 8.3, 7.1 Hz, 1H), 3.27 (ddd, J = 10.1, 5.0, 3.5 Hz, 1H), 2.92 – 2.74 (m, 2H), 2.65 – 2.32 (m, 2H), 2.21 (s, 3H), 2.16 – 2.07 (m, 1H), 1.98 – 1.84 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.44 , 133.33 , 133.18 , 130.47 , 128.66 , 128.31 , 126.77 , 126.38 , 125.86 , 125.15 , 120.56 , 94.17 , 81.45 , 40.95 , 36.37 (t, J = 21.1 Hz), 30.11 , 29.27 , 25.01 (t, J = 3.0 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -80.91 – -81.09 (m, 3F), -112.99 – -113.43 (m, 2F), -124.26 – -124.61 (m, 2F), -125.64 – -126.01 (m, 2F). FTIR (neat): $\tilde{v} = 3063$, 1718, 1508, 1397, 1355, 1219, 1165, 1132, 1017 cm⁻¹. HRMS (ESI): Exact mass calculated for C₂₂H₁₇OF₉Na ([M+Na]⁺): 491.1028, mass found: 491.1030.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-(pyridin-2-ylethynyl)decan-2-one (3l)



31 was synthesized according to GP2 with **11** (20 mg, 0.099 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 1/3) provided **31** as a liquid (25 mg, 60%); ¹H NMR (300 MHz, CDCl₃) δ 8.56 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H),

7.64 (td, J = 7.7, 1.8 Hz, 1H), 7.39 (dt, J = 7.8, 1.1 Hz, 1H), 7.22 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 3.13 (ddd, J = 10.0, 8.0, 5.0 Hz, 1H), 2.87 – 2.67 (m, 2H), 2.63 – 2.25 (m, 2H), 2.18 (s, 3H), 2.13 – 1.98 (m, 1H), 1.93 – 1.77 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.32 , 149.92 , 143.04 , 136.15 , 127.18 , 122.86 , 89.53 , 82.83 , 40.81 , 35.91 (t, J = 21.1 Hz), 30.06 , 28.76 , 24.59 (t, J = 3.1 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.8, 3.3 Hz, 3F), -113.29 – -113.57 (m, 2F), -124.31 – -124.58 (m, 2F), -125.73 – -126.00 (m, 2F). FTIR (neat): $\tilde{v} = 2931$, 1716, 1583, 1564, 1466, 1429, 1356, 1217, 1165, 1131, 1016 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₇H₁₄NOF₉Na ([M+Na]⁺): 442.0824, mass found: 442.0823.

5-(Cyclohexylethynyl)-7,7,8,8,9,9,10,10,10-nonafluorodecan-2-one (3m)

3m was synthesized according to GP2 with **1m** (21 mg, 0.103 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3m** as a liquid (19 mg, 44%); **¹H NMR** (300 MHz, CDCl₃) δ 6.04 (p, J = 2.1 Hz, 1H),

2.96 (td, J = 10.0, 9.3, 5.0 Hz, 1H), 2.77 – 2.56 (m, 2H), 2.49 – 1.86 (m, 11H), 1.77 – 1.52 (m, 6H). ¹³C **NMR** (75 MHz, CDCl₃) δ 207.61 , 134.45 , 120.39 , 86.42 , 85.08 , 40.93 , 36.31 (t, J = 21.1 Hz), 30.07 , 29.29 , 29.19 , 25.54 , 24.59 (t, J = 3.0 Hz), 22.28 , 21.49 . ¹⁹F **NMR** (282 MHz, CDCl₃) δ -81.04 (tt, J = 9.7, 3.3 Hz, 3F), -113.33 – -113.66 (m, 2F), -124.40 – -124.64 (m, 2F), -125.75 – -126.00 (m, 2F). **FTIR** (**neat**): $\tilde{v} = 2934$, 2364, 2335, 1718, 1437, 1355, 1217, 1164, 1131, 1108, 1022 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₈H₁₉OF₉Na ([M+Na]⁺): 445.1184, mass found: 445.1188.

5-(2,2,3,3,4,4,5,5,5-Nonafluoropentyl)undec-6-yn-2-one (3n)

 C_4F_9 C_4H_9 3n

3n was synthesized according to GP2 with **1n** (18 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3n** as a liquid

(16 mg, 40%); ¹H NMR (300 MHz, CDCl₃) δ 2.81 (ddd, J = 7.1, 4.8, 2.4 Hz, 1H), 2.65 (dt, J = 8.2, 6.3 Hz, 2H), 2.38 – 2.21 (m, 1H), 2.20 – 2.11 (m, 5H), 1.97 – 1.83 (m, 1H), 1.72 – 1.32 (m, 6H), 0.90 (t, J = 7.2 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 207.72, 83.43, 79.82, 40.97, 36.47 (t, J = 20.8 Hz), 30.89, 30.03, 29.37, 24.15 (t, J = 3.1 Hz), 21.85, 18.28, 13.52. ¹⁹F NMR (282 MHz, CDCl₃) δ -81.05 (tt, J = 9.7, 3.4 Hz, 3F), -113.37 – -113.67 (m, 2F), -124.47 – -124.72 (m, 2F), -125.73 – -126.03 (m, 2F). FTIR (neat): \tilde{v} = 2960, 1720, 1437, 1356, 1218, 1203, 1165, 1132, 1109 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₇H₁₄NOF₉Na ([M+Na]⁺): 421.1184, mass found: 421.1195.

5-(2,2,3,3,4,4,5,5,5-Nonafluoropentyl)undec-6-yn-2-one (30)

$$C_4F_9$$
TIPS

30 was synthesized according to GP2 with 10 (28 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided 30 as a liquid

(41 mg, 82%); ¹H NMR (300 MHz, CDCl₃) δ 2.92 (ddd, J = 10.3, 5.1, 3.6 Hz, 1H), 2.72 (t, J = 7.3 Hz, 2H), 2.47 – 2.07 (m, 5H), 2.03 – 1.90 (m, 1H), 1.72 – 1.60 (m, 1H), 1.08 – 1.03 (m, 21H). ¹³C NMR (75 MHz, CDCl₃) δ 207.42 , 107.95 , 83.78 , 40.74 , 36.49 (t, J = 21.1 Hz), 29.99 , 29.15 , 24.97 (t, J = 3.2 Hz), 18.57 , 18.49 , 11.17 . ¹⁹F NMR (282 MHz, CDCl₃) δ -81.08 (tt, J = 9.7, 3.4 Hz, 3F), -112.06 – -114.26 (m, 2F), -124.47 – -124.74 (m, 2F), -125.80 – -126.04 (m, 2F). FTIR (neat): \tilde{v} = 2944, 2893, 2867, 1721, 1464, 1356, 1234, 1133, 1018 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₇H₁₄NOF₉Na ([M+Na]⁺): 521.1893, mass found: 521.1888.

10,10,11,11,12,12,13,13,13-Nonafluoro-8-(phenylethynyl)tridecan-5-one (3p)

 $^{n}C_{4}H_{9}$ $C_{4}F_{9}$ Ph $\mathbf{3p}$

3p was synthesized according to GP2 with **1p** (24 mg, 0.099 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether =

30/1) provided **3p** as a liquid (29 mg, 64%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.43 – 7.36 (m, 2H), 7.30 (dt, J = 5.0, 2.0 Hz, 3H), 3.10 (dt, J = 8.0, 5.0 Hz, 1H), 2.71 (dd, J = 8.0, 6.5 Hz, 2H), 2.53 – 2.22 (m, 4H), 2.12 – 1.95 (m, 1H), 1.88 – 1.72 (m, 1H), 1.63 – 1.52 (m, 2H), 1.38 – 1.27 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 209.97 , 131.59 , 128.26 , 128.15 , 123.00 , 89.36 , 83.28 , 42.78 , 39.87 , 36.23 (t, J = 21.0 Hz), 29.12 , 26.00 , 24.74 (t, J = 3.1 Hz), 22.34 , 13.79 . ¹⁹**F NMR** (282 MHz, CDCl₃) δ -80.93 – -81.11 (m, 3F), -113.22 – -113.54 (m, 2F), -124.29 – -124.63 (m, 2F), -125.68 – -126.01 (m, 2F). **FTIR** (neat): $\tilde{v} = 2964$, 1715, 1599, 1491, 1444, 1413, 1380, 1355, 1220, 1169, 1132, 1070, 1019 cm⁻¹. **HRMS** (ESI): Exact mass calculated for C₂₁H₂₁OF₉Na ([M+Na]⁺): 483.1341, mass found: 483.1351.

$$C_4F_9$$

Ph

3q

3q was synthesized according to GP2 with 1q (23 mg, 0.101 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 30/1) provided 3q as

a liquid (28 mg, 62%); ¹H NMR (300 MHz, CDCl₃) δ 7.43 – 7.35 (m, 2H), 7.34 – 7.27 (m, 3H), 3.10 (ddd, J = 10.3, 5.1, 3.2 Hz, 1H), 2.76 (td, J = 6.8, 6.1, 1.6 Hz, 2H), 2.64 (p, J = 6.9 Hz, 1H), 2.56 – 2.18 (m, 2H), 2.03 (ddt, J = 13.4, 7.6, 3.8 Hz, 1H), 1.89 – 1.70 (m, 1H), 1.13 (dd, J = 7.0, 3.3 Hz, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 213.50 , 131.58 , 128.27 , 128.14 , 123.03 , 89.40 , 83.26 , 41.04 , 37.46 , 36.27 (t, J = 21.0 Hz), 29.17 , 24.72 (t, J = 3.0 Hz), 18.33 , 18.21 . ¹⁹F NMR (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.6, 3.3 Hz, 3F), -113.30 – -113.51 (m, 2F), -124.38 – -124.59 (m, 2F), -125.75 – -125.95 (m, 2F). FTIR (neat): \tilde{v} = 2975, 1713, 1491, 1355, 1217, 1132, 1019 cm⁻¹. HRMS (ESI): Exact mass calculated for C₂₁H₂₁OF₉Na ([M+Na]⁺): 469.1184, mass found: 469.1189.

6,6,7,7,8,8,9,9,9-Nonafluoro-1-phenyl-4-(phenylethynyl)nonan-1-one (3r)

 C_4F_9 Ph
3r

3r was synthesized according to GP2 with 1r (26 mg, 0.099 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 45/1) provided 3r as

a yellow solid (42 mg, 88%); **MP**: 43 °C; ¹**H NMR** (300 MHz, CDCl₃) δ 8.05 – 7.96 (m, 2H), 7.62 – 7.53 (m, 1H), 7.52 – 7.43 (m, 2H), 7.42 – 7.34 (m, 2H), 7.32 – 7.26 (m, 3H), 3.35 – 3.26 (m, 2H), 3.26 – 3.16 (m, 1H), 2.65 – 2.30 (m, 2H), 2.29 – 2.16 (m, 1H), 2.08 – 1.91 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 199.03 , 136.83 , 133.16 , 131.60 , 128.64 , 128.25 , 128.15 , 128.04 , 122.97 , 89.43 , 83.44 , 36.31 (t, J = 21.1 Hz), 35.95 , 29.70 , 24.92 . ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.01 (tt, J = 9.7, 3.3 Hz, 3F), -113.25 – -113.47 (m, 2F), -124.32 – -124.57 (m, 2F), -125.72 – -125.94 (m, 2F). **FTIR** (**neat**): \tilde{v} = 2951, 1680, 1599, 1491, 1451, 1354, 1282, 1229, 1196, 1129, 1102, 1013 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₂₃H₁₇OF₉Na ([M+Na]⁺): 503.1028, mass found: 503.1037.

Chiral **3r** was synthesized according to GP2 with chiral **1r** (26 mg, 0.099 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and

2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 45/1) provided chiral 3r as a yellow solid (39 mg, 82%); ¹H NMR (300 MHz, CDCl₃) δ 8.05 – 7.97 (m, 2H), 7.62 – 7.54 (m, 1H), 7.52 – 7.43 (m, 2H), 7.43 – 7.34 (m, 2H), 7.33 – 7.26 (m, 3H), 3.35 – 3.16 (m, 3H), 2.66 – 2.16 (m, 3H), 2.08 – 1.94 (m, 1H). The pure product was analyzed by chiral HPLC. Chiral HPLC (Chiralcel OJ-RH column with guard, 20 °C, 1 mL/min, MeCN:H₂O = 65:35); Elution time: t_{major} = 8.734 min and t_{minor} = 10.047 min, enantiomeric excess (7%).

7,7,8,8,9,9,10,10,10-Nonafluoro-5-methyl-5-(phenylethynyl)decan-2-one (3s)

O C₄F₉

3s was synthesized according to GP2 with **1s** (21 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 15/1) provided **3s** as a liquid

(31 mg, 73%); ¹H NMR (300 MHz, CDCl₃) δ 7.41 – 7.34 (m, 2H), 7.30 (dt, J = 5.1, 1.6 Hz, 3H), 2.72 (dd, J = 8.7, 7.0 Hz, 2H), 2.51 – 2.23 (m, 2H), 2.20 (s, 3H), 2.10 – 1.86 (m, 2H), 1.48 (d, J = 1.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 207.54 , 131.54 , 128.25 , 128.11 , 123.02 , 92.25 , 83.06 , 40.24 (t, J = 20.0 Hz), 39.43 , 35.71 , 32.79 , 30.06 , 26.97 (t, J = 2.1 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -81.06 (td, J = 9.7, 4.8 Hz, 3F), -110.35 – -112.84 (m, 2F), -124.41 – -124.69 (m, 2F), -125.54 – -125.77 (m, 2F). FTIR (neat): \tilde{v} = 2942, 1719, 1491, 1354, 1218, 1131, 1071, 1025 cm⁻¹. HRMS (ESI): Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 455.1028, mass found: 455.1046.

7,7,8,8,9,9,10,10,10-Nonafluoro-6,6-dimethyl-5-(phenylethynyl)decan-2-one (3t)

C₄F₉

3t was synthesized according to GP2 with 1t (23 mg, 0.101 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2a (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 15/1) provided 3t as a liquid

(19 mg, 42%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.38 – 7.32 (m, 2H), 7.29 (dt, J = 5.1, 1.8 Hz, 3H), 2.86 – 2.60 (m, 2H), 2.41 – 2.22 (m, 1H), 2.20 – 1.98 (m, 5H), 1.52 (d, J = 2.0 Hz, 3H), 1.48 (s, 3H). ¹³**C**

NMR (75 MHz, CDCl₃) δ 207.17, 131.43, 128.26, 127.97, 123.22, 95.04, 81.73, 48.60 – 47.83 (m), 43.66, 35.51 (d, J = 2.4 Hz), 29.76, 29.47 (d, J = 5.7 Hz), 26.93 – 26.61 (m), 20.97 – 20.60 (m). ¹⁹F NMR (282 MHz, CDCl₃) δ -80.90 (tt, J = 9.9, 3.5 Hz, 3F), -108.57 – -112.47 (m, 2F), -119.98 – -123.35 (m, 2F), -124.34 – -127.10 (m, 2F). FTIR (neat): \tilde{v} = 2984, 1720, 1598, 1491, 1419, 1351, 1233, 1217, 1166, 1016 cm⁻¹. HRMS (ESI): Exact mass calculated for C₂₀H₁₉OF₉Na ([M+Na]⁺): 469.1184, mass found: 469.1192.


6,6,7,7,8,8,9,9,9-Nonafluoro-2,2-dimethyl-1-phenyl-4-(phenylethynyl)nonan-1-one (3u)

 $\begin{array}{c} O \\ Ph \\ \\ Ph \\ \\ \textbf{3u} \end{array}$

3u was synthesized according to GP2 with **1u** (29 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 50/1) provided **3u** as

a liquid (23 mg, 57%); ¹H NMR (300 MHz, CDCl₃) δ 7.71 – 7.64 (m, 2H), 7.43 – 7.30 (m, 3H), 7.22 (dd, J = 6.1, 2.4 Hz, 5H), 3.23 – 3.10 (m, 1H), 2.57 – 2.23 (m, 3H), 2.00 (dd, J = 13.8, 3.7 Hz, 1H), 1.48 (s, 3H), 1.46 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 207.83 , 138.74 , 131.39 , 130.79 , 128.07 , 128.02 , 127.99 , 123.00 , 90.42 , 83.90 , 47.58 , 45.62 , 37.24 (t, J = 20.8 Hz), 27.44 , 25.94 , 22.25 (t, J = 2.9 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -81.01 (tt, J = 9.7, 3.3 Hz, 3F), -113.08 – -113.54 (m, 2F), -124.35 – -124.76 (m, 2F), -125.60 – -126.06 (m, 2F). FTIR (neat): \tilde{v} = 2971, 1674, 1491, 1353, 1217, 1131, 1019 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{25}H_{21}OF_{9}Na$ ([M+Na]⁺): 531.1341, mass found: 531.1342.

7-Phenyl-5-(2,2,2-trifluoroethyl)hept-6-yn-2-one (3v)



3v was synthesized according to GP2 with **1a** (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2b** (60 μL, 0.180 mmol, 0.588 g/mL in DME) in 1.25 mL of DME under visible-light at 50 °C for 8 h. Then second part of **2b** (60 μL, 0.180 mmol, 0.588 g/mL in DME)was added and the reaction was reacted for another 16 h. Purification by flash column

chromatography (pentane/ethyl ether = 10/1) provided 3v as a liquid (11 mg, 41%); ¹H NMR (300

MHz, CDCl₃) δ 7.42 – 7.36 (m, 2H), 7.34 – 7.27 (m, 3H), 3.05 – 2.93 (m, 1H), 2.83 – 2.63 (m, 2H), 2.52 – 2.39 (m, 1H), 2.37 – 2.25 (m, 1H), 2.19 (s, 3H), 2.06 – 1.94 (m, 1H), 1.83 – 1.73 (m, 1H). ¹³C **NMR** (75 MHz, CDCl₃) δ 207.51, 131.59, 128.27, 128.16, 126.54 (q, J = 117.8 Hz), 122.99, 88.95, 83.42, 40.87, 39.34 (q, J = 27.9 Hz), 30.10, 28.51, 26.96 (q, J = 3.0 Hz). ¹⁹F **NMR** (282 MHz, CDCl₃) δ -64.12. **FTIR** (**neat**): $\tilde{v} = 2929$, 1718, 1491, 1381, 1255, 1164, 1140, 1111 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₅H₁₅OF₃Na ([M+Na]⁺): 291.0966, mass found: 291.0967.


7,7,8,8,9,9,10,10,11,11,12,12,12-Tridecafluoro-5-(phenylethynyl)dodecan-2-one (3w)

O C₆F₁₃

3w was synthesized according to GP2 with **1a** (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2c** (39 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3w** as a

liquid (32 mg, 62%); ¹H NMR (300 MHz, CDCl₃) δ 7.42 – 7.37 (m, 2H), 7.33 – 7.27 (m, 3H), 3.10 (ddt, J = 9.9, 8.0, 5.0 Hz, 1H), 2.84 – 2.65 (m, 2H), 2.59 – 2.23 (m, 2H), 2.19 (s, 3H), 2.03 (dtd, J = 15.3, 7.3, 4.5 Hz, 1H), 1.81 (dtd, J = 10.1, 7.6, 3.9 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 207.45 , 131.58 , 128.27 , 128.18 , 122.95 , 89.26 , 83.32 , 40.88 , 36.29 (t, J = 21.0 Hz), 30.08 , 29.09 , 24.73 (t, J = 2.9 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ -80.80 (tt, J = 10.0, 5.0 Hz, 3F), -113.09 – -113.30 (m, 2F), -121.58 – -121.93 (m, 2F), -122.66 – -123.00 (m, 2F), -123.42 – -123.69 (m, 2F), -125.97 – -126.23 (m, 2F). FTIR (neat): \tilde{v} = 2954, 1719, 1491, 1444, 1360, 1318, 1235, 1190, 1164, 1144, 1122, 1049, 1027 cm⁻¹. HRMS (ESI): Exact mass calculated for $C_{20}H_{15}OF_{13}Na$ ([M+Na]⁺): 541.0808, mass found: 541.0819.

7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heptadecafluoro-5-(phenylethynyl)tetradecan-2-one (3x)



3x was synthesized according to GP2 with 1a (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2d (48 μ L, 0.182 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by

flash column chromatography (pentane/ethyl ether = 10/1) provided $3\mathbf{x}$ as a yellow solid (34 mg, 55%); **MP**: 39 °C; ¹**H NMR** (300 MHz, CDCl₃) δ 7.43 – 7.35 (m, 2H), 7.30 (dt, J = 3.8, 2.7 Hz, 3H), 3.09 (ddd, J = 9.9, 8.0, 4.9 Hz, 1H), 2.84 – 2.64 (m, 2H), 2.53 – 2.23 (m, 2H), 2.19 (s, 3H), 2.11 – 1.97 (m, 1H), 1.88 – 1.75 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 207.45 , 131.59 , 128.27 , 128.18 , 122.96 , 89.27 , 83.32 , 40.89 , 36.30 (t, J = 21.0 Hz), 30.08 , 29.09 , 24.73 (t, J = 3.1 Hz). ¹⁹**F NMR** (282 MHz, CDCl₃) δ -80.79 (t, J = 9.8 Hz, 3F), -113.18 (t, J = 14.5 Hz, 2F), -121.37 – -121.68 (m, 2F), -121.70 – -122.04 (m, 4F), -122.45 – -122.90 (m, 2F), -123.30 – -123.72 (m, 2F), -125.90 – -126.26 (m, 2F). **FTIR** (neat): \tilde{v} = 2944, 1718, 1600, 191, 1443, 1370, 1329, 1236, 1200, 1145, 1134, 1113, 1027 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₂₂H₁₅OF₁₇Na ([M+Na]⁺): 641.0744, mass found: 641.0740.

7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-Henicosafluoro-5-(phenylethynyl)hexadec an-2-one (3y)

 $C_{10}F_{21}$ Ph3y

3y was synthesized according to GP2 with **1a** (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2e** (116 mg, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column chromatography (pentane/ethyl ether = 10/1) provided **3y** as

a white solid (34 mg, 47%); **MP**: 69 °C; ¹**H NMR** (300 MHz, CDCl₃) δ 7.43 – 7.35 (m, 2H), 7.34 – 7.27 (m, 3H), 3.10 (ddt, J = 9.9, 8.0, 4.9 Hz, 1H), 2.86 – 2.64 (m, 2H), 2.60 – 2.23 (m, 2H), 2.19 (s, 3H), 2.11 – 1.96 (m, 1H), 1.90 – 1.72 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 207.46 , 131.59 , 128.28 , 128.18 , 122.96 , 89.27 , 83.32 , 40.89 , 36.31 (t, J = 21.0 Hz), 30.09 , 29.10 , 24.74 (t, J = 3.0 Hz). ¹⁹**F NMR** (282 MHz, CDCl₃) δ -80.71 – -80.84 (m, 3F), -113.08 – -113.30 (m, 2F), -121.31 – -122.07 (m, 10F), -122.68 (brs, 2F), -123.51 (brs, 2F), -125.92 – -126.24 (m, 2F). **FTIR** (**neat**): $\tilde{v} = 2962$, 1718, 1491, 1444, 1372, 1211, 1150, 1110, 1053 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₂₄H₁₅OF₂₁Na ([M+Na]⁺): 741.0680, mass found: 741.0680.

8-Chloro-7,7,8,8-tetrafluoro-5-(phenylethynyl)octan-2-one (3z)

3z was synthesized according to GP2 with 1a (20 mg, 0.100 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and 2f (47 mg, 0.179 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by flash column

chromatography (pentane/ethyl ether = 10/1) provided 3z as a liquid (27 mg, 81%); ^{1}H NMR (300 MHz, CDCl₃) δ 7.43 – 7.36 (m, 2H), 7.34 – 7.27 (m, 3H), 3.08 (ddt, J = 10.0, 8.0, 5.0 Hz, 1H), 2.85 – 2.63 (m, 2H), 2.60 – 2.23 (m, 2H), 2.19 (s, 3H), 2.11 – 1.96 (m, 1H), 1.88 – 1.76 (m, 1H). ^{13}C NMR (75 MHz, CDCl₃) δ 207.51 , 131.58 , 128.26 ,

128.14 , 123.00 , 89.39 , 83.28 , 40.91 , 36.02 (t, J = 21.4 Hz), 30.09 , 29.03 , 25.08 (t, J = 2.8 Hz). ¹⁹**F** NMR (282 MHz, CDCl₃) δ -71.45 (t, J = 2.3 Hz, 2F), -113.02 – -113.09 (m, 2F). **FTIR** (neat): $\tilde{v} = 2958$, 1717, 1599, 1419, 1443, 1374, 1252, 1212, 1148, 1094, 1050, 1026 cm⁻¹. **HRMS** (ESI): Exact mass calculated for C₁₆H₁₅O³⁵ClF₄Na ([M+Na]⁺): 357.0640, mass found: 357.0650.

8,8,9,9,10,10,11,11,11-Nonafluoro-6-(phenylethynyl)undecan-2-one (3va)

 C_4F_9 Ph

3va

3va was synthesized according to GP2 with **1v** (21 mg, 0.098 mmol), LiHMDS (0.12 mL, 0.120 mmol, 1.0 M in THF solution), LiOH (1 mg, 0.042 mmol), DABCO (17 mg, 0.152 mmol), and **2a** (31 μ L, 0.180 mmol) in 1.25 mL of DME under visible-light at 50 °C for 18 h. Purification by

flash column chromatography (pentane/ethyl ether = 10/1) provided **3va** as a liquid (28 mg, 66%); ¹**H NMR** (300 MHz, CDCl₃) δ 7.43 – 7.35 (m, 2H), 7.29 (ddd, J = 3.4, 2.5, 1.5 Hz, 3H), 3.06 (tt, J = 8.3, 5.3 Hz, 1H), 2.57 – 2.21 (m, 4H), 2.16 (s, 3H), 1.96 – 1.86 (m, 1H), 1.86 – 1.72 (m, 1H), 1.71 – 1.55 (m, 2H). ¹³**C NMR** (75 MHz, CDCl₃) δ 208.11 , 131.60 , 128.23 , 128.03 , 123.15 , 89.79 , 82.88 , 43.01 , 35.96 (t, J = 21.0 Hz), 34.69 , 29.87 , 25.15 (t, J = 3.2 Hz), 21.15 . ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.03 (tt, J = 9.7, 3.3 Hz, 3F), -113.34 – -113.61 (m, 2F), -124.36 – -124.60 (m, 2F), -125.73 – -125.95 (m, 2F). **FTIR** (**neat**): \tilde{v} = 2942, 1718, 1599, 1491, 1444, 1356, 1222, 1167, 1133 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₉H₁₇OF₉Na ([M+Na]⁺): 455.1028, mass found: 455.1030.

4. Follow-up chemistry

7,7,8,8,9,9,10,10,10-nonafluoro-5-(phenylethynyl)decan-2-ol (4)

To a flame-dried Schlenk tube equipped with a magnetic stir bar LiAlH₄ (0.050 mmol, 1 M in THF, 0.050 mL), THF (1 mL) and 3a (21 mg, 0.050 mmol) were added sequentially under Ar atmosphere. The mixture was allowed to stir at 80 °C for 3 h. After that, the reaction was quenched with 5 mL of H₂O at 0 °C. Then 5 mL of saturated potassium sodium tartrate solution was added into this mixture.

OH C₄F₉ Ph **4**, d.r. = 1:1 The mixture was extracted with 5 mL of ethyl ether three times. The organic phase was combined, washed with brine and dried over Na_2SO_4 . The solvent was then removed and the residue was purified by flash column chromatography (pentane/ethyl acetate = 10/1) to provide 4 as a liquid (16 mg, 76%, d.r. = 1:1); ¹H NMR (600 MHz, C_6D_6) δ 7.46 – 7.40 (m, 2H), 7.00

-6.94 (m, 3H), 3.47 - 3.41 (m, 1H), 2.92 - 2.84 (m, 1H), 2.26 - 2.15 (m, 1H), 1.99 - 1.90 (m, 1H), 1.56 - 1.46 (m, 2H), 1.38 - 1.30 (m, 2H), 0.93 (d, J = 6.2 Hz, 1.46H), & 0.93 (d, J = 6.1 Hz, 1.49H), 0.65 (s, 1H). ¹³C **NMR** (75 MHz, C_6D_6) δ 131.89, 128.54, 128.19, 123.84, 90.61 & 90.48, 83.46 & 83.40, 67.45 & 66.94, 36.81 & 36.50, 36.21 , 36.72 – 35.92 (m), 32.09 & 31.76, 25.67 (t, J = 3.3 Hz) & 25.34 (t, J = 2.8 Hz), 23.86 & 23.77. ¹⁹F **NMR** (282 MHz, C_6D_6) δ -81.06 – -81.21 (m), -112.01 – -114.47 (m), -124.15 – -124.41 (m), -125.72 – -125.92 (m). **FTIR** (**neat**): $\tilde{v} = 3349$, 2969, 2928, 1355, 1217, 1131, 1070, 1016 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for $C_{18}H_{17}OF_9Na$ ([M+Na]⁺): 443.1028, mass found: 443.1002.

7,7,8,8,9,9,10,10,10-Nonafluoro-5-phenethyldecan-2-one (5)

 C_4F_9

To a flame-dried Schlenk tube equipped with a magnetic stir bar Palladium 5% on activated carbon (5 mg, 0.0023 mmol), 3a (21 mg, 0.050 mmol), and MeOH (1 mL) were added sequentially under H₂ atmosphere. The mixture was allowed to stir at room temperature with a H₂ balloon for 23 h. After

that, the solvent was then removed and the residue was purified by flash column chromatography (pentane/ethyl ether = 20/1) to provide **5** as a liquid (17 mg, 80%); ¹**H NMR** (600 MHz, CDCl₃) δ 7.26 - 7.17 (m, 2H), 7.16 - 7.06 (m, 3H), 2.61 - 2.50 (m, 2H), 2.37 (t, J = 7.7 Hz, 2H), 2.08 (s, 3H), 2.05 - 1.79 (m, 3H), 1.74 - 1.59 (m, 4H). ¹³**C NMR** (75 MHz, CDCl₃) δ 141.55, 128.47, 128.26, 126.01, 40.44, 36.09, 33.85 (t, J = 21.0 Hz), 32.54, 30.56, 29.92, 27.80. ¹⁹**F NMR** (282 MHz, CDCl₃) δ -81.05 (tt, J = 9.7, 3.3 Hz), -112.94 - -113.11 (m), -124.33 - -124.51 (m), -125.72 - -125.91 (m). **FTIR** (**neat**): \tilde{v} = 2923, 1719, 1497, 1455, 1356, 1217, 1131, 1046, 1022 cm⁻¹. **HRMS** (**ESI**): Exact mass calculated for C₁₈H₁₉OF₉Na ([M+Na]⁺): 445.1184, mass found: 45.1188.

(2-Methyl-5-(2,2,3,3,4,4,5,5,5-nonafluoropentyl)cyclopent-1-en-1-yl)(phenyl)methanone (6)

C₄F₉ O

To a flame-dried Schlenk tube equipped with a magnetic stir bar 3a (21 mg, 0.050 mmol), MeOH (1 mL) and TfOH (0.2 μ L, 0.002 mmol) were added sequentially under Ar atmosphere. The mixture was allowed to stir at 80 °C for 5 h. After that, the solvent was removed and the residue was purified by flash column chromatography (pentane/ethyl acetate = 80/1) provided 6 as a liquid (16 mg, 76%); ³ ¹H NMR (600

(pentane/ethyl acetate = 80/1) provided **6** as a liquid (16 mg, 76%);³ ¹**H NMR** (600 MHz, C_6D_6) δ 7.71 – 7.65 (m, 2H), 7.13 – 7.03 (m, 3H), 3.68 – 3.51 (m, 1H), 2.93 – 2.66 (m, 1H), 2.08 – 1.75 (m, 4H), 1.51 – 1.39 (m, 1H), 1.23 (s, 3H). ¹³**C NMR** (75 MHz, C_6D_6) δ 195.25, 149.77, 139.64, 137.59, 132.55, 129.04, 128.66, 41.66, 38.74, 34.27 (t, J = 20.8 Hz), 29.61, 16.69. ¹⁹**F NMR** (282 MHz, C_6D_6) δ -80.88 – -81.24 (m), -110.49 – -114.70 (m), -124.08 – -124.43 (m), -125.55 – -125.84 (m). **FTIR** (neat): \tilde{v} = 2935, 1640, 1349, 1216, 1131, 1101, 1017 cm⁻¹. **HRMS** (ESI): Exact mass calculated for $C_{18}H_{15}OF_9Na$ ([M+Na]+): 441.0871, mass found: 441.0847.

(5-Methyl-2-(2,2,3,3,4,4,5,5,5-nonafluoropentyl)cyclopent-1-en-1-yl)(phenyl)methanone (6)

C₄F₉
O
Ph


To a flame-dried Schlenk tube equipped with a magnetic stir bar AuCl₃ (0.6 mg, 0.002 mmol), AgSbF₆ (2.0 mg, 0.006 mmol), **3a** (42 mg, 0.100 mmol), and toluene (1 mL) were added sequentially under Ar atmosphere. The mixture was allowed to stir at 100 °C for 18 h. After that, 5 mL of H₂O was added to the mixture and then the aqueous phase was extracted with 5 mL of ethyl acetate three times. The combined organic

phase was washed with brine and dried over Na₂SO₄. The solvent was then removed and the residue was purified by flash column chromatography (pentane/ethyl acetate = 350/1) provided **6** as a liquid (25 mg, 60%);⁴ ¹**H NMR** (300 MHz, CDCl₃) δ 7.81 – 7.72 (m, 2H), 7.60 – 7.52 (m, 1H), 7.50 – 7.42 (m, 2H), 3.70 – 3.54 (m, 1H), 2.70 – 2.44 (m, 3H), 2.40 – 2.30 (m, 1H), 2.03 – 1.86 (m, 1H), 1.85 – 1.73 (m, 1H), 1.62 (d, 7H). ¹³**C NMR** (75 MHz, CDCl₃) δ 196.50, 150.82, 139.00, 137.49, 132.84, 128.87, 128.61, 41.38, 39.06, 34.04 (t, J = 21.0 Hz), 29.62, 16.98. ¹⁹**F NMR** (282 MHz, CDCl₃) δ -80.98 – 81.24 (m), -111.01 – -115.27 (m), -124.37 – -124.58 (m), -125.79 – -126.05 (m).

5. References:


- (1) G. A. Phillips, C. Palmer, A. C. Stevens, M. L. Piotrowski, D. S. R. Dekruyf, B. L. Pagenkopf, Tetrahedron Letter 2015, 56, 6052-6055.
- (2) P. G. Cozzi, S. Alesi, Chem. Commun. 2004, 2448-2449.

- (3) T. Jin, F. Yang, C. Liu, Y. Yamamoto, Chem. Commun. 2009, 3533-3535.
- (4) T. Jin, Y. Yamamoto, Org. Lett. 2007, 9, 5259-5262.




240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 fl (ppm)

Dec20-2016. 461. fid — stu tang txj 503 — carbon CDC13 /opt/topspin av1 22









240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 fl (ppm)

Dec07-2016. 221. fid — stu txj 528 — carbon CDC13 /opt/topspin av1 19




240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)


Jan17-2017. 261. fid — TXJ-539-C — carbon CDC13 /opt/topspin av1 40



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 fl (ppm)


Dec09-2016.601.fid — stu tang txj 532 — carbon CDC13 /opt/topspin av1 39








230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)

Jan13-2017. 651. fid — TXJ-602-C — carbon CDC13 /opt/topspin av1 51











:40 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -2 f1 (ppm)


Jan13-2017. 621. fid — TXJ-535-C — carbon CDC13 /opt/topspin av1 48






230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -2 f1 (ppm)


Jan13-2017. 631. fid — TXJ-580-C — carbon CDC13 /opt/topspin av1 49








230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)


Jan13-2017. 641. fid — TXJ-596-C — carbon CDC13 /opt/topspin av1 50






























230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)


Jan18-2017. 341. fid — TXJ-614-1-C — carbon_256 CDCl3 /opt/topspin av1 33

















240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)

Feb22-2017. 91. fid — TXJ-697-C — carbon_256 CDC13 /opt/topspin av1 31







Acq. Operator : kischkewitz

Acq. Instrument : Instrument 1 Location : Vial 1

Injection Date : 11.05.2017 10:09:11

Inj Volume : 15.0 µl

: C:\CHEM32\1\METHODS\AK STUDER\STANDARD METHODS\M20_S.M Acq. Method

: 04.04.2017 13:39:48 by prekel

Analysis Method: C:\CHEM32\1\METHODS\AK STUDER\STANDARD METHODS\M1 S.M

Last changed : 11.05.2017 10:55:10 by kischkewitz

(modified after loading)

: standard method M1_S, solvent system 90:10, time 60 min, flow 1 mL/min, 25 Method Info

°C, 15 microL injection vol.


Sample Info : OD-H

Instrument Conditions : At Start At Stop 25.0 25.0 Column Temp. (left) : 25.0 Column Temp. (right) 25.0 °C Pressure 132.9 134.6 bar : 1.000 ml/min Flow : 1.000

Detector Lamp Burn Times: Current On-Time Accumulated On-Time DAD 1, UV Lamp : 0.27
DAD 1, Visible Lamp : OFF 3733.6 h 567.1 h

Solvent Description

PMP1 , Solvent A : Cyclohexan
PMP1 , Solvent B : Cyclohexan:Isoprop 90:10 PMP1 , Solvent B



Signal 2: DAD1 B, Sig=250,16 Ref=360,100

	RetTime [min]			Area [mAU*s]	Height [mAU]	Area %
1	15.136	MM	4.2695	6.28758e4	245.44820	49.5738
2	23.195	MM	3.2754	6.39568e4	325.44220	50.4262

1.26833e5 570.89040 Totals :

Acq. Operator : kischkewitz

Acq. Instrument : Instrument 1 Location : Vial 2

Injection Date : 11.05.2017 10:56:21

Inj Volume : 15.0 μl

Acq. Method : C:\CHEM32\1\METHODS\AK STUDER\STANDARD METHODS\M20_S.M

Last changed : 11.05.2017 10:40:42 by kischkewitz

Analysis Method: C:\CHEM32\1\METHODS\AK STUDER\STANDARD METHODS\M1 S.M


Last changed : 11.05.2017 12:56:08 by kischkewitz

(modified after loading)

Method Info : standard method M1_S, solvent system 90:10, time 60 min, flow 1 mL/min, 25

°C, 15 microL injection vol.


Sample Info : OD-H




Signal 1: DAD1 A, Sig=260,4 Ref=360,100


Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	용
1	14.621	MM	4.3488	2.34345e4	89.81277	62.2583
2	22.950	MM	3.2419	1.42063e4	73.03435	37.7417

Totals: 3.76407e4 162.84712

















S48







































S53






























230 220 210 200 190 180 170 160 150 140 130 120 110 f1 (ppm)

Jan29-2017.71. fid — TXJ-644-C — carbon CDCl3 /opt/topspin avi 42





100 90


60

10


S63


































































Data file C:\Cnem32\I\DATA\TANG\TX060000004.D

Sample Name: TXJ658

Acq. Operator : prekel
Acq. Instrument : Instrument 1 Location : Vial 1
Injection Date : 11.04.2017 15:31:48

Inj Volume : 5.0 μl

Acq. Method : C:\CHEM32\1\METHODS\RP CHIRAL\RP CHIRAL_65-35.M

Last changed : 11.04.2017 15:31:35 by prekel

(modified after loading)

Analysis Method : C:\CHEM32\1\METHODS\RP NEUTRAL 1ML\RP_65-35_1.M


Last changed : 24.06.2016 10:35:17 by prekel Method Info : Standard Method RP_65:35_1

Flow: 1mL/min; 20°C; Injection 5µL; time: 50min

Solvent System:MeCN/H2O=65/35

isocratic

Sample Info : OJ-RH ACN/H2O



Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000

Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Data File C:\CHEM32\1\DATA\TANG\TXJ745000001.D

Sample Name: TXJ745

Acq. Method

Acq. Operator : prekel
Acq. Instrument : Instrument 1

Injection Date : 11.04.2017 16:05:49

Inj Volume : 5.0 μl : C:\CHEM32\1\METHODS\RP CHIRAL\RP CHIRAL 65-35.M

Location : Vial 1

Last changed : 11.04.2017 16:03:39 by prekel

(modified after loading)

Analysis Method: C:\CHEM32\1\METHODS\RP NEUTRAL 1ML\RP_65-35_1.M

Last changed : 24.06.2016 10:35:17 by prekel
Method Info : Standard Method RP_65:35_1


Flow: 1mL/min; 20°C; Injection 5µL; time: 50min

Solvent System: MeCN/H2O=65/35

isocratic

Sample Info : OJ-RH

ACN/H2O



Area Percent Report

Sorted By : Signal


Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Data File C:\CHEM32\1\DATA\TANG\TXJ745000001.D Sample Name: TXJ745


Signal 1: DAD1 B, Sig=230,8 Ref=360,100


Totals: 2.31067e4 1403.17700


*** End of Report ***




























__-64.12











































30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 f1 (ppm)

Jun20-2017. 703. fid — stu jang txj 819 — f19cpd C6D6 /opt/topspin av1 23

